Teva Pharmaceutical Industries Limited

Technion Research & Development Foundation Limited

Other

Yeda Research and Develpment & Co. Ltd

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Teva Pharmacaetical Industries Ltd.

Jeffrey Sterling

David Lerner

Haim Yellin

Ruth Levy

John P Finberg

Moussa B Youdim

Alex Veinberg

Moussa B H Youdim

Tirtsah Berger-Paskin

Michael Chorev

Yaacov Herzig

Marta Weinstock-Rosin

Tamar Goren

Yacov Herzig

John P M Finberg

Ben-Zion Weiner

Ramy Lidor-Hadas

Eliezer Bahar

Istvan Miskolczi

Raul Suchi

Harel Rosen

Leonid Bronov

Dalia Medini-Green

Berta Iosefzon

Tirtsah Berger-Peskin

Irun R Cohen

Abraham Nudelman

Nina Finkelstein

Meir Shinitzky

Raanan Margalit

Ehud Keinan

Yuriy Raizi

Raphael Nudelman

Tivadar Tamas

Gyorgy Toth

Eliezer Falb

Isaac Milman

Ferenc Rantal

Konstantin Ulanenko

Jaacov Herzig

Danielle Hirsch

Vladimir Ioffe

Moussa Bh Youdim

Ben Z Weiner

Andras Zekany

Mussa B Youdim

Varda Gilad

Gad Gilad

Eliot Slovin

Dinora Barasch

Basic esters of fatty alcohols of the general formula: R1-O&#x2014;CO-A or pharmaceutically acceptable salts thereof, wherein R1 is C-Calkyl or C-Calkenyl, and A is a residue containing at least one acyclic or cyclic amino group and/or at least one heteroaromatic ring containing a tertiary or quaternary nitrogen atom, are anti-inflammatory and immunomodulatory agents, useful in the treatment of immunologically-mediated inflammation, as adjuvants for antigens involved in both cellular and humoral responses.

Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents

Disclosed are novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective in treating neurologic disorders, including Parkinson's disease and multiple sclerosis.

Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use

Disclosed are enantiomers of amino-phenyl-acetic acid octadec-9-(Z)-enyl ester, and salts thereof, including pharmaceutical compositions, uses and a process for the manufacture thereof.

Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses

The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.

Rasagiline formulations and processes for their preparation

This invention is directed to compounds of the following formula (I):  

Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents

This invention is directed to compounds of the following formula:wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, Ris hydrogen Calkyl, Ris hydrogen, Calkyl, or optionally substituted propargyl and Rand Rare each independently hydrogen, Calkyl, Caryl, Caralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Aminoindan derivatives

The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

The subject invention provides R(&plus;)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(&plus;)-N-propargyl-1-aminoindan, or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(&plus;)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan

The subject invention provides R(&plus;)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(&plus;)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.

This invention is directed to compounds of the following formula

This invention is directed to compounds of the following formula:

Phenylethylamine derivatives

The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.

Pharmaceutical compositions of the R-enantiomer of N-propargyl

Growing community of inventors

Jerusalem, Israel

Jeffrey Sterling